LUCD Projected Dividend Yield
Lucid Diagnostics Inc ( NASDAQ : LUCD )Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. Co. is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Co.'s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. 21 YEAR PERFORMANCE RESULTS |
LUCD Dividend History Detail LUCD Dividend News LUCD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |